Anti-Infective Drugs Global Market Report 2018

1
Anti-Infective Drugs Global Market Report 2018
Including Antivirals Antibiotics Antifungals
Others (Antihelmethic, Antiprotozoal) Covering
Gilead, Merck Co., GlaxosmithKline,
Bristol-Myers Squibb Company, Johnson Johnson
Feb 2018
2
Reasons to Purchase

• Outperform competitors using accurate up to date
  demand-side dynamics information.
• Identify growth segments for investment.
• Facilitate decision making on the basis of
  historic and forecast data and the drivers and
  restraints on the market.
• Create regional and country strategies on the
  basis of local data and analysis.
• Stay abreast of the latest customer and market
  research findings
• Benchmark performance against key competitors.
• Develop strategies based on likely future
  developments.
• Utilize the relationships between key data sets
  for superior strategizing.
• Suitable for supporting your internal and
  external presentations with reliable high
  quality data and analysis
• Gain a global perspective on the development of
  the market.
• Report will be updated with the latest data and
  delivered to you within 3-5 working days of
  order.
• Scope
• Markets Covered Antivirals Antibiotics
  Antifungals Others (Antihelmethic,
• Antiprotozoal)
• Companies Mentioned Gilead, Merck Co.,
  GlaxosmithKline, Bristol-Myers Squibb Company,
  Johnson Johnson
• Countries Brazil, China, France, Germany, India,
  Italy, Japan, Spain, Russia, UK, USA and
  Australia.
• Regions Asia-Pacific, Western Europe, Eastern
  Europe, North America, South America, Middle
  East And Africa

3
Anti-Infective Drugs Market Characteristics

• Infectious diseases are disorders caused by
  several pathogenic organisms such as bacteria,
  viruses, fungi or parasites. These diseases can
  be transmitted or spread from one person to
  another through direct contact or indirect
  contact. Anti- infective drugs are used to treat
  or prevent these infectious diseases by
  inhibiting the spread of an infectious agent
  (static) or by killing the infectious agent
  (cidal). The market numbers within this briefing
  are restricted to pharmaceutical (drug)
  treatments and do not cover biologic treatments
  for these conditions which are included in a
  separate briefing.
• Based on the target pathogenic organism,
  anti-infective drugs are classified as follows
• Antiviral Drugs are used to
• Antibacterial Drugs/Antibiotic Drugs are used to
  treat or
• Antifungal Drugs are used to
• Antiparasitic Drugs are used to
• Antiprotozoal Drugs are used to
• Antimalarial Drugs are used to treat or
• Antihelminthic Drugs are used to
• Ectoparasiticide Drugs are used to

In this report market value is defined as the
revenues organizations earn by selling their
goods and services within the specified market,
based on the price at which they sell. Only
goods and services traded between entities are
included.
4
The revenues for a specified geography are
consumption values that is, they are revenues
generated by organizations in the specified
geography within the specified market,
irrespective of where they are produced.
5
Anti-Infective Drugs Market Historic Growth
The global anti-infective drugs market grew from
X billion in 2013 to X billion in 2017 at a
compound annual growth rate (CAGR) of X. The
chart and table below shows the year-on-year
growth of the global anti- infective drugs
market during 2013 2017.
Drivers of the Market Restraints on the Market
6
Anti-Infective Drugs Market Forecast Growth
The global anti-infective drugs market is
expected to grow from XX billion in 2017 to
132.6 billion in 2021 at a compound annual
growth rate (CAGR) of XX. This growth is mainly
due to the growing infectious diseases caused by
bacteria, viruses, fungi and the expected
increase in global healthcare expenditure.
According to the Institute for Health Metrics
and Evaluation (IHME), global spending on
healthcare is expected to increase to 18.28
trillion by 2040. The chart and table below
shows the year-on-year growth of the global anti-
infective drugs market during 2017 - 2021.
Drivers of the Market Restraints on the Market
7
Anti-Infective Drugs Market Segmentation
The chart and table below shows the split of the
anti-infective drugs market in 2017.
The total market value for anti-infective drugs
was X billion in 2017. The markets that are
covered include Antivirals Antibiotics
Antifungals Others (Antihelmethic,
Antiprotozoal). Antivirals was the X largest
segment in the anti-infective drugs market with
X share of the market. The market value for the
antivirals was X billion in 2017. Antibiotics
made up around X share of the market. The market
value for the antibiotics was X billion in 2017.
8
Anti-Infective Drugs Market Regional And Country
Analysis
The Asia Pacific was the largest region in the
anti-infective drugs market in 2017,
anti-infective drugs for X billion or X market
share. North America was the x largest region
anti-infective drugs for X billion or X market
share. Western Europe was the x largest region
anti-infective drugs for X billion or X market
share.
9
Anti-Infective Drugs Market Competitive Landscape
The leading competitors in the global
anti-infective drugs market are Gilead, Merck
Co., GlaxosmithKline, Bristol-Myers Squibb
Company, Johnson Johnson. The chart and table
below displays the percentage market share of the
top players in the anti-infective drugs market
industry.
Gilead generated revenues of XX billion for the
financial year 2016, an XX decrease from the
previous year. Merck Co. generated revenues of
XX billion for the financial year 2016, an XX
increase from the previous year. GlaxosmithKline
generated revenues of XX billion for the
financial year 2016, an XX increase from the
previous year. Bristol-Myers Squibb Company
generated revenues of XX billion for the
financial year 2016, an XX decrease from the
previous year.
10
Johnson Johnson generated revenues of XX
billion for the financial year 2016, an XX
decrease from the previous year. Pfizer generated
revenues of XX billion for the financial year
2016, an XX increase from the previous
year. AbbVie generated revenues of XX billion
for the financial year 2016, an XX decrease
from the previous year. Novartis AG generated
revenues of XX billion for the financial year
2016, an XX decrease from the previous
year. Bayer AG generated revenues of XX billion
for the financial year 2016, an XX decrease
from the previous year. Otsuka generated revenues
of XX billion for the financial year 2016, an
XX decrease from the previous year. Company
Profile Gilead Overview Gilead was the largest
competitor in the anti-infective drugs market in
2017 with a 13.81 market share. Gilead is an
American biopharmaceutical company that
discovers, develops and commercializes
therapeutics for areas such as cardiovascular
and inflammation/respiratory diseases,
hematology/oncology, human immunodeficiency virus
(HIV), liver diseases such as chronic hepatitis
C virus (HCV) infection and chronic hepatitis B
virus (HBV) infection. The company was founded
in 1987 and is headquartered in Foster City,
California, United States. Products and
Services The companys products for various
diseases include The HIV products include The
Liver Diseases products include
11
The Cardiovascular products include The
Inflammation/Respiratory products
include Strategy Gileads growth strategy aims
to focus on development of products for HIV,
viral hepatitis and other diseases through
collaborations with other companies, medical
research institutions and Financial
Performance Gileads Hepatitis C, HIV and Other
products generated revenues of XX billion in
2016, a XX decrease from the previous year. The
company had a market Merck Co. Overview Produc
ts and Services Strategy Financial
Performance GlaxosmithKline Overview Products
and Services Strategy Financial
Performance Bristol-Myers Squibb
Company Overview Products and Services
Strategy Financial Performance Johnson
Johnson Overview Products and Services
Strategy Financial Performance